Get the Stockscreener App
67.59
0.07%
-0.05
After Hours:
67.58
-0.01
-0.01%
Disc Medicine Inc stock is traded at $67.59, with a volume of 305.87K.
It is down -0.07% in the last 24 hours and up +3.70% over the past month.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
See More
Previous Close:
$67.64
Open:
$68
24h Volume:
305.87K
Relative Volume:
0.48
Market Cap:
$2.58B
Revenue:
-
Net Income/Loss:
$-212.18M
P/E Ratio:
-11.28
EPS:
-5.9897
Net Cash Flow:
$-181.33M
1W Performance:
+0.49%
1M Performance:
+3.70%
6M Performance:
-23.46%
1Y Performance:
+39.07%
1-Day Range:
$66.70
$69.31
1-Week Range:
$64.98
$69.45
52-Week Range:
$40.00
$99.50
Disc Medicine Inc Stock (IRON) Company Profile
Name
Disc Medicine Inc
Sector
Industry
Phone
(617) 674-9274
Address
321 ARSENAL STREET, SUITE 101, WATERTOWN
Compare IRON vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRON
Disc Medicine Inc
|
67.59 | 2.58B | 0 | -212.18M | -181.33M | -5.9897 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-25 | Resumed | Stifel | Buy |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jun-11-25 | Resumed | Raymond James | Strong Buy |
| Feb-27-25 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-04-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-23-24 | Initiated | Jefferies | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-22-24 | Initiated | Wells Fargo | Overweight |
| Apr-01-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-19-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-09-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-07-23 | Initiated | H.C. Wainwright | Buy |
| May-17-23 | Initiated | Raymond James | Outperform |
| Apr-28-23 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-21-23 | Initiated | Stifel | Buy |
| Apr-20-23 | Initiated | Morgan Stanley | Overweight |
| Mar-23-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Disc Medicine Inc Stock (IRON) Latest News
Disc Medicine (NASDAQ:IRON) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Earnings Flash (IRON) Disc Medicine Posts Q1 Net Loss $1.65 a Share, vs. FactSet Est of $1.65 Loss - marketscreener.com
Disc Medicine (NASDAQ: IRON) posts wider Q1 loss but holds $730M cash - Stock Titan
Disc Medicine 1Q 2026: Net income $(63.5M), EPS $(1.65) — 10-Q Summary - TradingView
IRON: Phase 3 bitopertin trial enrollment completed; strong cash position supports pipeline into 2029 - TradingView
Disc Medicine finishes Phase 3 rare-disease trial, eyes Q4 data - Stock Titan
IRON: Net loss widened to $63.5M in Q1 2026 as bitopertin's FDA review was delayed for more data - TradingView
Disc Medicine (NASDAQ: IRON) posts Q1 2026 loss and advances late-stage trials - Stock Titan
How Investors Are Reacting To Disc Medicine (IRON) After FDA Letter Triggers Shareholder Investigation - simplywall.st
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are ... - Caledonian Record
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
Avoiding Lag: Real-Time Signals in (IRON) Movement - Stock Traders Daily
Disc Medicine, Inc. $IRON Shares Acquired by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
Jennison Associates LLC Takes Position in Disc Medicine, Inc. $IRON - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.IRON - PR Newswire
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action InvestigationIRON - Morningstar
Pictet Asset Management Holding SA Grows Stock Holdings in Disc Medicine, Inc. $IRON - MarketBeat
Disc Medicine (IRON) Projected to Post Earnings on Thursday - MarketBeat
IRON Investor News: If You Have Suffered Losses in Disc - GlobeNewswire
[ARS] Disc Medicine, Inc. SEC Filing - Stock Titan
Disc Medicine (NASDAQ: IRON) details 2026 proxy, pay and board votes - Stock Titan
ROSEN, A LONGSTANDING LAW FIRM, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action InvestigationIRON - TMX Newsfile
Disc Medicine prices upsized securities offering to raise total $250M - MSN
Disc Medicine and Sanofi reportedly face delays for FDA national priority review vouchers - MSN
Disc Medicine plunges on FDA complete response letter for bitopertin - MSN
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action InvestigationIRON - TMX Newsfile
Will Insider 10b5-1 Sales and New ASCO Data Shift Disc Medicine's (IRON) Narrative? - Sahm
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - Scott Coop
IRON Price Today: Disc Medicine, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Disc Medicine (NASDAQ:IRON) Upgraded at Wall Street Zen - MarketBeat
Disc Medicine, Inc. (NASDAQ:IRON) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Disc Medicine Completes Key Phase 1b Study of DISC-0974 in CKD Anemia: What Investors Should Watch - TipRanks
Disc Medicine to present myelofibrosis trial data at ASCO meeting By Investing.com - Investing.com India
Discipline and Rules-Based Execution in IRON Response - Stock Traders Daily
Disc Medicine Insider Sells $380K in Stock Amid 70% One-Year Surge - Yahoo Finance
Disc Medicine to present myelofibrosis trial data at ASCO meeting - Investing.com
Disc Medicine, Inc. to Present RALLY-MF Trial Data on DISC-0974 at ASCO Annual Meeting 2026 - Quiver Quantitative
Disc Medicine announced that the Phase 2 clinical trial data of its drug DISC-0974 in patients with myelofibrosis-associated anemia (RALLY-MF) have been selected for an oral presentation at the annual meeting of the American Society of Clinical Oncology. - Bitget
Myelofibrosis anemia data lands ASCO oral presentation on June 2 - Stock Titan
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action InvestigationIRON - TMX Newsfile
Short Interest in Disc Medicine, Inc. (NASDAQ:IRON) Rises By 21.4% - MarketBeat
Disc Medicine Inc Stock (IRON) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):